Background
Optimizing methods for the study of allergic rhinitis (AR), especially when using samples likely containing small amounts of material for analysis, ensures the integrity of results that may potentially enhance the understanding of AR disease mechanisms. In order to conduct future mRNA expression analysis, examining the differential expression of AR mediators such as IL33, TSLPR, HPGDS, and CRTH2 at baseline and 6 hours following Nasal Allergen Challenge (NAC) in allergic individuals, this study aims to optimize the RNA isolation, reverse transcription (RT), and qPCR protocols used for the study of nasal mucosal samples.
Methods
Several RNA isolation and RT kits were evaluated using nasal scrapings from healthy individuals, similar to those collected from allergic participants. These kits were evaluated based on the yield and purity of RNA and cDNA, assessed using spectrophotometry, qPCR amplification, and gel electrophoresis. Reference gene analysis using cDNA isolated from allergic participants was conducted using qPCR and the statistical software GenEx (MultID). Primer design and evaluation of primers for the targets of interest—IL33, TSLPR, HPGDS, and CRTH2—was also pursued.
Anzeige
Results
RNA isolation and RT kit optimization determined that the Life Technologies-Qiagen (LT-Q) kit combination produced cDNA with maximal purity and qPCR efficiency compared with the other kit combinations evaluated. Reference gene analysis demonstrated that expression of ubiquitin C (UBC) showed limited variability among the differing conditions (time point and study) of nasal sample collection. Primer evaluation yielded inconsistent results.
Conclusions
Future processing of nasal scraping samples should use the optimal LT-Q kit combination. Following successful primer evaluation, the expression levels of the targets of interest in the allergic nasal mucosal cDNA samples at both baseline and 6h post-NAC will be conducted via the optimized qPCR reaction, using UBC as a reference gene.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.